13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001823138
Total reported value
$8.7B
$8.7B
18 檔
4.9%
As reported in its official Q1 2024 Form 13F filing, Two Seas Capital LP's tracked investment portfolio stood at $8.7B with 18 total positions.
During Q1 2024, Two Seas Capital LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including INDV, ROIV, ABUS) accounted for 4.9% of total reported equity market value during Q1 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | INDV | Indivior Pharmaceuticals, Inc. | Stock-Other | 55.60% | — | -4.05% | |
| 2 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 16.37% | -2.95% | -6.79% | |
| 3 | ABUS | Arbutus Biopharma CORP | Stock-Other | 3.96% | -1.37% | -13.27% | |
| 4 | IMVT | Immunovant Inc | Stock-Other | 3.43% | -0.60% | +89.69% | |
| 5 | ESPR 4 11-15-25Bond | Esperion Therapeutics | Bond | 3.31% | — | +17.60% | |
| 6 | META | Meta Platforms Inc-class A | Stock-Comm Services | 3.04% | — | +22.09% | |
| 7 | VST | Vistra CORP | Stock-Utilities | 2.69% | -0.75% | — | |
| 8 | CORZ | Core Scientific Inc | Stock-Tech | 2.66% | -5.01% | — | |
| 9 | ESPR | Esperion Therapeutics Inc | Stock-Other | 2.19% | — | -45.80% | |
| 10 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 1.57% | — | — | |
| 11 | SONO | Sonos Inc | Stock-Other | 1.51% | -0.19% | EXIT | |
| 12 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 1.05% | — | — | |
| 13 | OMEX | Odyssey Marine Exploration | Stock-Other | 0.92% | -0.05% | -9.79% | |
| 14 | GOOGL | Alphabet Inc-cl A | Stock-Comm Services | 0.72% | — | — | |
| 15 | SHC | Sotera Health Co | Stock-Other | 0.71% | -0.75% | — | |
| 16 | CORZZ | Core Scientific Inc - 29 | Stock-Other | 0.11% | -0.01% | — | |
| 17 | TRML | Tourmaline Bio Inc | Stock-Other | 0.10% | — | — | |
| 18 | CORZW | Core Scientific Inc - 27 | Stock-Other | 0.07% | -0.08% | — |
According to official SEC Form 13F filings, Two Seas Capital LP reported a total U.S. public equity portfolio value of $8.7B across 18 disclosed positions in Q1 2024.
During Q1 2024, Two Seas Capital LP's top holdings by market value included INDV (55.6%)、ROIV (16.4%)、ABUS (4.0%). The largest single position, INDV, represented 55.6% of total portfolio value.
In Q1 2024, Two Seas Capital LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.